Clinical Trial Update: A Study of RO5036505 in Patients With Moderate to Severe Asthma [Phase 2]

View source ↗

Summary

A Phase 2 study of the Roche compound RO5036505 in moderate-to-severe asthma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• RO5036505 (RO5036505)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Asthma | Phase 2 | Status: WITHDRAWN